Serotonin and Norepinephrine Reuptake Inhibitors

Area of Science:

• Pharmacology and Therapeutics
• Neuroscience
• Psychiatry

Background:

• Serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors represent a distinct class of antidepressants.
• Unlike selective serotonin reuptake inhibitors (SSRIs), many SNRIs feature ascending dose-response curves.
• This chapter reviews the chemistry, pharmacology, metabolism, safety, clinical use, and indications of these agents.

Purpose of the Study:

• To provide a comprehensive overview of serotonin and norepinephrine reuptake inhibitors.
• To detail the pharmacological profiles, including potency and binding affinity ratios for 5-HT and NE transporters.
• To discuss the clinical applications, safety, and adverse effects of specific SNRI antidepressants.

Main Methods:

• Review of chemical structures and pharmacological properties of SNRIs.
• Analysis of pharmacokinetic data, including metabolism (e.g., CYP2D6, CYP3A4) and half-life.
• Summarization of safety profiles, adverse effects, and drug-drug interaction potentials.

Main Results:

• Venlafaxine exhibits dose-dependent 5-HT and NE reuptake inhibition, with potential for blood pressure elevation at higher doses.
• Desvenlafaxine, an active metabolite of venlafaxine, has a favorable drug-drug interaction profile.
• Duloxetine shows potent and balanced 5-HT/NE reuptake inhibition, with common side effects including nausea and hypertension.
• Milnacipran and levomilnacipran are effective for fibromyalgia, with potential for blood pressure and pulse elevation.

Conclusions:

• SNRIs like venlafaxine, desvenlafaxine, duloxetine, milnacipran, and levomilnacipran offer diverse therapeutic options for major depressive disorder and other conditions.
• Understanding their distinct pharmacological profiles, dose-response curves, and potential side effects is crucial for optimal clinical use.
• Awareness of drug-drug interactions, particularly with CYP enzyme metabolism and MAOIs (risk of serotonin syndrome), is essential for patient safety.